Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at University of Arizona, Department of Pediatrics discuss research in cancer vaccines
April 29th, 2008
New investigation results, 'A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model,' are detailed in a study published in Molecular Cancer Therapeutics. According to a study from the United States, "We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity." "Administration of TUBO CRCL triggered...
Source: Cancer Weekly (2008-04-29)
|
